全文获取类型
收费全文 | 17644篇 |
免费 | 1476篇 |
国内免费 | 575篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 223篇 |
妇产科学 | 214篇 |
基础医学 | 4197篇 |
口腔科学 | 221篇 |
临床医学 | 1102篇 |
内科学 | 2778篇 |
皮肤病学 | 154篇 |
神经病学 | 2241篇 |
特种医学 | 258篇 |
外国民族医学 | 1篇 |
外科学 | 1042篇 |
综合类 | 2004篇 |
现状与发展 | 3篇 |
一般理论 | 1篇 |
预防医学 | 1230篇 |
眼科学 | 143篇 |
药学 | 1667篇 |
2篇 | |
中国医学 | 927篇 |
肿瘤学 | 1242篇 |
出版年
2024年 | 51篇 |
2023年 | 287篇 |
2022年 | 459篇 |
2021年 | 618篇 |
2020年 | 478篇 |
2019年 | 474篇 |
2018年 | 466篇 |
2017年 | 532篇 |
2016年 | 560篇 |
2015年 | 623篇 |
2014年 | 865篇 |
2013年 | 1063篇 |
2012年 | 918篇 |
2011年 | 989篇 |
2010年 | 930篇 |
2009年 | 942篇 |
2008年 | 971篇 |
2007年 | 901篇 |
2006年 | 832篇 |
2005年 | 725篇 |
2004年 | 688篇 |
2003年 | 574篇 |
2002年 | 503篇 |
2001年 | 481篇 |
2000年 | 414篇 |
1999年 | 338篇 |
1998年 | 325篇 |
1997年 | 272篇 |
1996年 | 291篇 |
1995年 | 272篇 |
1994年 | 214篇 |
1993年 | 185篇 |
1992年 | 169篇 |
1991年 | 129篇 |
1990年 | 112篇 |
1989年 | 116篇 |
1988年 | 108篇 |
1987年 | 62篇 |
1986年 | 77篇 |
1985年 | 98篇 |
1984年 | 109篇 |
1983年 | 50篇 |
1982年 | 84篇 |
1981年 | 69篇 |
1980年 | 63篇 |
1979年 | 55篇 |
1978年 | 40篇 |
1977年 | 29篇 |
1976年 | 41篇 |
1973年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
《Vaccine》2022,40(32):4296-4300
Advanced computational methodologies suggested SARS-CoV-2, nonstructural proteins ORF1AB, ORF3a, as the source of immunodominant peptides for T cell presentation. T cell immunity is long-lasting and compatible with COVID-19 pathology. Based on the supporting clinical data, nonstructural SARS-CoV-2 protein vaccines could provide global immunity against COVID-19. 相似文献
2.
3.
Lipid nanoparticles (LNPs) are becoming popular as a means of delivering therapeutics, including those based on nucleic acids and mRNA. The mRNA-based coronavirus disease 2019 vaccines are perfect examples to highlight the role played by drug delivery systems in advancing human health. The fundamentals of LNPs for the delivery of nucleic acid- and mRNA-based therapeutics, are well established. Thus, future research on LNPs will focus on addressing the following: expanding the scope of drug delivery to different constituents of the human body, expanding the number of diseases that can be targeted, and studying the change in the pharmacokinetics of LNPs under physiological and pathological conditions. This review article provides an overview of recent advances aimed at expanding the application of LNPs, focusing on the pharmacokinetics and advantages of LNPs. In addition, analytical techniques, library construction and screening, rational design, active targeting, and applicability to gene editing therapy have also been discussed. 相似文献
4.
5.
6.
7.
8.
Nerve growth factor (NGF) and NGF receptors were measured in cortex and hippocampus of rats treated with drugs affecting cholinergic neurotransmission. High (Kd= 0.045nM) and low (Kd= 21nM) affinity125I-NGF binding sites were present in both cortical and hippocampal membranes with hippocampus containing higher numbers of both sites than cortex. Chronic treatment of rats with the muscarinic receptor antagonist scopolamine (5 mg/kg, twice daily) decreased the density of high- and low-affinity sites by 50–90% in cortical and hippocampal membranes. These changes were seen after 7 days, but not 3 days, of scopolamine treatment. Chronic infusion of physostigmine (1 mg/kg/day) using minipumps increased the number of high- and low-affinity sites in cortex 3- and 6-fold, respectively. The changes in receptor-binding parameters induced by physostigmine were transient as they were evident after 3 days of treatment, but returned to control levels after 7 days. NGF content in cortex and hippocampus was reduced by about 50% following 7, but not 3, days of chronic physostigmine infusion. In contrast, scopolamine treatment failed to change NGF levels in the cholinergic neuronal target regions but it decreased NGF content in the septal area. The content of NGF mRNA in the cortex measured by Northern blot analysis failed to change following either scopolamine or physostigmine treatment. The results suggest that levels of NGF and NGF receptors in the target regions of cholinergic neurons are regulated by the extent of cholinergic neurotransmitter activity. 相似文献
9.
PTH has diverse effects on bone metabolism: anabolic when given intermittently, catabolic when given continuously. The cellular
mechanisms underlying the varying target cell response are not clear yet. PTH induces RGS-2, a member of the Regulator of
G-protein Signaling protein family, via cAMP/PKA, and inactivates PKC-mediated signaling. To investigate intracellular signaling
pathways with different PTH concentration-time patterns, we treated UMR 106-01 osteoblast-like cells in a perfusion system.
PTH was administered intermittently (4 min/h, 10−7 M) or continuously at an equivalent cumulative dose (6.6 × 10−9 M). cAMP was measured using radioimmunoassay, mRNA levels using real-time rtPCR and ribonuclease protection assay, and protein
levels using Western immunoblotting. A single PTH pulse transiently increased cAMP levels by 2000% ± 1200%. In contrast to
continuous PTH exposure, cAMP induction remained unchanged with intermittent PTH, ruling out desensitization of the PTH receptor.
In continuously perfused cells, RGS-2 abundance was three to five times higher than in cells intermittently exposed to PTH
for up to 12 h. MKP-1 and -3 were significantly less induced with pulsatile PTH; exposure-mode-dependent differences in MMP-13
and IGFBP-5 were small. Pulsatile but not continuous PTH administration prevents PTHrP receptor desensitization and accumulation
of RGS-2 in osteoblasts, which should preserve PKC-dependent signaling. 相似文献
10.